77 related articles for article (PubMed ID: 6253346)
21. [Screening of dominant epitopes of antigens related to antibodies in the sera of patients with nasopharyngeal carcinoma].
Zhang Y; Xiao XB; Zhang CQ; Li JL; Sun Y; Ye YZ; Feng KT
Ai Zheng; 2004 Sep; 23(9):999-1004. PubMed ID: 15363190
[TBL] [Abstract][Full Text] [Related]
22. [Expression and significance of EBV LMP2A in nasopharyngeal cancer specimens].
Xu J; Yao K; Yu C; Chen X; Li B; Sun H; Zhou F
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Jun; 19(11):484-7. PubMed ID: 16124641
[TBL] [Abstract][Full Text] [Related]
23. [The expression of HLA, Epstein-Barr virus nuclear antigen and the infiltration of T lymphocyte subsets in nasopharyngeal biopsy tissues].
Chen X; Cai Y; Sun N
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1994; 29(1):6-9. PubMed ID: 8031607
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus and nasopharyngeal carcinoma: is there an etiologic relationship?
Henderson BE; Louie EW; Jing JS; Alena B
J Natl Cancer Inst; 1977 Nov; 59(5):1393-5. PubMed ID: 198562
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus serological markers for nasopharyngeal carcinoma in Thailand.
Puthavathana P; Sutthent R; Vitavasiri A; Wasi C; Chantarakul N; Thongcharoen P
Southeast Asian J Trop Med Public Health; 1991 Sep; 22(3):326-31. PubMed ID: 1818381
[TBL] [Abstract][Full Text] [Related]
26. A prospective evaluation of patients with nasopharyngeal carcinoma: an overview.
Neel HB
J Otolaryngol; 1986 Jun; 15(3):137-44. PubMed ID: 3014165
[TBL] [Abstract][Full Text] [Related]
27. Anti-Epstein Barr virus antibody in nasopharyngeal carcinoma.
Hsu MM; Chiou JF; McCabe BF
Ann Otol Rhinol Laryngol; 1974; 83(1):19-25. PubMed ID: 4359674
[No Abstract] [Full Text] [Related]
28. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
[TBL] [Abstract][Full Text] [Related]
29. Lymphocyte subsets and EB virus antibodies in nasopharyngeal carcinoma.
Lynn TC; Hsieh RP; Tu SM
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1985 May; 18(2):70-8. PubMed ID: 2994964
[TBL] [Abstract][Full Text] [Related]
30. Combined determination of Epstein-Barr virus-related antibodies and antigens for diagnosis of nasopharyngeal carcinoma.
Luo YL; Ou GP; Chi PD; Liang YN; Liu YH; Huang MY
Ai Zheng; 2009 Jan; 28(1):76-8. PubMed ID: 19448423
[TBL] [Abstract][Full Text] [Related]
31. [Significance of virus-specific antibodies to EBV-antigens in patients with nasopharyngeal carcinoma (author's transl)].
Wilmes E; Wolf H; Deinhardt F; Naumann HH
Laryngol Rhinol Otol (Stuttg); 1979 Dec; 58(12):911-5. PubMed ID: 231716
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus antibodies in Sudanese patients with nasopharyngeal carcinoma: a preliminary report.
Malik MO; Banatvala J; Hutt MS; Abu-Sin AY; Hidaytallah A; El-Hadi AE
J Natl Cancer Inst; 1979 Feb; 62(2):221-4. PubMed ID: 216831
[TBL] [Abstract][Full Text] [Related]
33. Herbal medicine use, Epstein-Barr virus, and risk of nasopharyngeal carcinoma.
Hildesheim A; West S; DeVeyra E; De Guzman MF; Jurado A; Jones C; Imai J; Hinuma Y
Cancer Res; 1992 Jun; 52(11):3048-51. PubMed ID: 1317256
[TBL] [Abstract][Full Text] [Related]
34. [Carcinomas of the nasopharynx. Relationship between histological type and anti-Epstein-Barr virus serology (author's transl)].
Micheau C; de The G; Orofiamma B; Schwaab G; Brugere J; Tursz T; Sancho-Garnier H; Cachin Y
Nouv Presse Med; 1980 Jan; 9(1):21-4. PubMed ID: 6243770
[TBL] [Abstract][Full Text] [Related]
35. [Expression of CD25+ lymphocytes in nasopharyngeal carcinoma and its association with EBV infection].
Liu W; Han HX
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):94-7. PubMed ID: 16495186
[TBL] [Abstract][Full Text] [Related]
36. [Quantitative and localized detection of Epstein-Barr virus infectious status in nasopharyngeal carcinoma tissue].
Jiang WH; Zhao SP; Yin ZH; Li F; Chen ZH; Xiao JY
Ai Zheng; 2005 Jul; 24(7):796-800. PubMed ID: 16004803
[TBL] [Abstract][Full Text] [Related]
37. Immunologic study on nasopharyngeal carcinoma patients: correlation of in vivo and in vitro reactivity to phytohemagglutinin.
Hsu MM; Lo P
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1983 Feb; 16(1):20-32. PubMed ID: 6851721
[TBL] [Abstract][Full Text] [Related]
38. Immunity to antigens associated with a cell line derived from nasopharyngeal cancer (NPC) in non-Chinese NPC patients.
Levine PH; De Thé GB; Brugere G; Schwaab G; Mourali N; Herberman RB; Ambrosioni JC; Revol P
Int J Cancer; 1976 Feb; 17(2):155-60. PubMed ID: 175025
[TBL] [Abstract][Full Text] [Related]
39. Antibody-dependent cellular cytotoxicity and disease course in North American patients with nasopharyngeal carcinoma: a prospective study.
Pearson GR; Neel HB; Weiland LH; Mulroney SE; Taylor W; Goepfert H; Huang A; Levine P; Lanier A; Pilch B
Int J Cancer; 1984 Jun; 33(6):777-82. PubMed ID: 6329967
[TBL] [Abstract][Full Text] [Related]
40. The expression of Ia-antigen on nasopharyngeal carcinomas xenografted into nude mice.
Ebbers J; Koldovsky P; Vosteen KH
Arch Otorhinolaryngol; 1985; 242(2):209-15. PubMed ID: 2998311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
